BPC-157 + TB-500 blend (oral) (Oral) dosing

What it is

This is a pill that contains two peptides at once. A peptide is a short chain of amino acids, the building blocks of proteins. Each pill holds 500 micrograms (mcg) of BPC-157 and 500 mcg of TB-500.

BPC-157 stands for Body Protection Compound 157. It is a 15-amino-acid fragment of a protective protein found in human stomach juice, and it is studied for repair of tendons, muscle, gut lining, and blood vessels. It is unusual because it survives stomach acid, which is what makes a swallowed form possible.

TB-500 is a synthetic version of thymosin beta-4, a 43-amino-acid protein found in nearly every human cell. It is studied for wound healing, muscle and tendon repair, and reduced inflammation and scarring.

The pairing is nicknamed the "Wolverine Stack" after the Marvel character who heals from any injury. The two peptides work on different stages of healing, so their effects add up rather than overlap.

There is nothing to mix and no needle. You swallow the pill.

Two things to know before reading on. First, almost everything written about this pairing, including the research and the timelines below, comes from the injectable blend. TB-500 does not share BPC-157's stability in stomach acid, so how much of the TB-500 half survives a swallowed pill is not known. Second, neither peptide is approved for human use. Both are banned by the World Anti-Doping Agency and by the UFC, NFL, NCAA, NHL, MLB, NAIA, and PGA, and in 2023 the FDA classed both as Category 2 bulk drug substances, which bars them from compounded medicines.

A fixed 500 mcg / 500 mcg oral co-formulation of BPC-157 and TB-500, one dose unit per pill.

BPC-157 arm: a stable synthetic 15-amino-acid fragment of a protective protein in human gastric juice. Angiogenic and cytoprotective rather than hormonal, acting through growth factor signalling, nitric oxide modulation, VEGFR2 upregulation, FAK–paxillin activation, and increased growth hormone receptor expression in tendon fibroblasts. Gastric acid stability is the property that makes an oral presentation viable. Half-life is under 30 minutes.

TB-500 arm: a synthetic version of thymosin beta-4, a 43-amino-acid actin-sequestering protein present in nearly every cell. Low molecular weight, no extracellular matrix binding, systemic distribution; releases the tetrapeptide Ac-SDKP on metabolism.

The rationale for the pairing is mechanistic non-overlap: BPC-157 builds the vascular and growth-factor infrastructure for local repair, TB-500 drives cell migration, stem and satellite cell recruitment, and anti-fibrotic remodelling systemically. No controlled study has tested the combination against either peptide alone; the only combination data is a 4-patient intra-articular subgroup in Lee and Padgett (2021).

Route caveats specific to this presentation. The oral route forfeits site-targeting entirely, which is how the injectable achieves peri-lesional BPC-157 concentration. Gastric stability is documented for BPC-157, not for TB-500, and TB-500 is not considered to share it. No oral bioavailability figure exists for either arm, so equivalence to the injectable 250–500 mcg daily protocol cannot be computed.

Regulatory: both peptides are FDA Category 2 bulk drug substances (2023), WADA-prohibited under S0, banned by UFC, NFL, NCAA, NHL, MLB, NAIA, and PGA, and not legal for sale as a drug, food, or supplement in the US.

How it works

Healing is not one event. It is a chain of steps: controlling inflammation, growing new blood vessels, moving repair cells into the damaged area, rebuilding tissue, and tidying up the result. Each of these peptides handles different steps.

BPC-157 builds the infrastructure. It makes cells more sensitive to the body's own repair signals, a bit like fitting more antennas so they pick up the signal better. That triggers new blood vessels, widens existing ones so more oxygen and nutrients arrive, helps cells anchor at the injury, and makes tendon cells more responsive to growth hormone. Because it amplifies existing signals, it needs damaged tissue to work on. It also lowers inflammation.

TB-500 is the repair crew. Cells move by rearranging an internal scaffold protein called actin. TB-500 stores actin building blocks and releases them when repair cells need to travel, so those cells can physically move to the injury. It also grows blood vessels by a separate route, recruits stem cells, and, as the body breaks it down, releases a small fragment called Ac-SDKP that calms inflammation and reduces scar tissue, so wounds heal with organised tissue rather than a lumpy scar.

Put together: one peptide sets up the site and the blood supply; the other brings in the workers and makes sure the new tissue forms properly. They also fight inflammation through different routes, so they cover more ground.

With an injection, BPC-157 works hardest near where it is placed while TB-500 travels everywhere. With a pill, both enter through the gut, so there is no local targeting. The BPC-157 half is known to survive stomach acid; the TB-500 half is not known to.

Repair is a cascade of inflammation control, angiogenesis, cell migration, matrix rebuilding, and remodelling; the two arms address different stages.

BPC-157 upregulates VEGFR2 expression, driving angiogenesis via the Akt–eNOS pathway; modulates nitric oxide synthesis for vasodilation; activates FAK–paxillin to support cell migration and anchoring at the injury; and increases growth hormone receptor expression in tendon fibroblasts. It reduces COX-2 expression and inflammatory cytokines including IL-6 and TNF-alpha, and promotes fibroblast activity and collagen production. Its action is amplification of existing injury signals rather than de novo signalling, so it is inert without a lesion. Half-life is under 30 minutes; it is hepatically metabolised, renally excreted, and detectable in urine for up to 4 days.

TB-500 sequesters G-actin (actin is roughly 10% of cellular protein content) and hands monomers to profilin on demand, driving cytoskeletal reorganisation for long-range cell migration independent of matrix binding. It stimulates VEGF directly and acts on endothelial cells, giving a second angiogenic pathway. Its metabolite Ac-SDKP is anti-inflammatory and anti-fibrotic, suppressing myofibroblast activity and disorganised scar. It mobilises stem and satellite cells and acts as a myoblast chemoattractant. No published subcutaneous pharmacokinetics exist; the circulating "approximately 10 days" half-life figure is not from a published study.

Complementarity: receptor upregulation (VEGFR2) plus ligand stimulation (VEGF); local anchoring (FAK–paxillin) plus long-range migration (actin); COX-2/IL-6/TNF-alpha reduction plus Ac-SDKP; collagen synthesis plus anti-fibrotic remodelling; local plus systemic coverage. Synergy has not been confirmed in a controlled design.

Oral-specific: both arms enter via the gastrointestinal tract, removing the local/systemic split that defines the injectable. Only the BPC-157 arm has demonstrated gastric stability.

What it does

Taken together, the two peptides are used to speed repair of soft tissue.

For tendons and ligaments, the main use, BPC-157 helps tendon cells grow, survive, and repair locally, while TB-500 draws repair cells into the tissue, improves the strength of healing ligaments, and prevents the stiff bands and adhesions that limit movement after injury. Common targets include Achilles, rotator cuff, patellar tendon, tennis and golfer's elbow, and ACL and MCL sprains.

For muscle, BPC-157 supports regeneration of muscle fibres with better structure, and TB-500 attracts muscle precursor cells to the damage.

For wounds, BPC-157 grows blood vessels, re-covers the surface, and lays down collagen; in rats, TB-500 increased surface re-covering by 42% at day 4 and 61% at day 7 while reducing scarring.

For joints, both reduce inflammation by different routes and support remodelling, usually over a longer run.

For the gut, the BPC-157 half helps heal ulcers, protects against damage from anti-inflammatory painkillers, and supports recovery in inflammatory bowel conditions in animal studies. TB-500 adds nothing here, so for gut-only goals plain oral BPC-157 may be the better choice.

BPC-157 also stimulates collagen for skin and hair, protects the brain from free radical damage, supports memory and mood, eases pain through dopamine and serotonin, and helps normalise blood pressure.

The injectable blend has a clear advantage for several injuries at once, because TB-500 finds damage anywhere while BPC-157 works hardest at the injection site. With a pill there is no injection site, so that split does not apply.

Primary application is tendon and ligament repair: BPC-157 promotes tendon fibroblast outgrowth, survival, and migration with localised repair; TB-500 promotes fibroblast migration into connective tissue, improves biomechanical properties of healing ligament (Xu et al., 2013, medial collateral ligament in rats, with more uniform fibre bundles and larger collagen fibril diameters), and prevents adhesion and fibrous band formation. Applications include Achilles, rotator cuff, patellar tendinopathy, lateral and medial epicondylitis, and ACL and MCL sprains.

Muscle: BPC-157 drives fibre regeneration with improved structure and biomechanics in animal models; TB-500 is a myoblast chemoattractant.

Wound healing: BPC-157 promotes angiogenesis, re-epithelialisation, and collagen deposition; TB-500 increased re-epithelialisation by 42% at day 4 and 61% at day 7 in rat wounds (Malinda et al., 1999) and produced organised mature collagen with minimal scarring and no loss of breaking strength (Ehrlich and Hazard, 2010).

Joint support: dual-pathway anti-inflammatory activity plus remodelling support for chronic inflammation and degenerative wear.

Post-surgical recovery after ACL reconstruction, rotator cuff repair, meniscus surgery, and soft tissue procedures, with surgeon approval.

Enteric activity is BPC-157-only: ulcer healing, protection against NSAID-induced mucosal damage, and colonic healing in inflammatory bowel models. TB-500 lacks gastric stability, so oral BPC-157 alone may be more appropriate for gut-specific goals.

BPC-157 additionally: collagen synthesis with dermal and hair effects; CNS antioxidant protection, memory preservation, mood regulation, and analgesia via central dopamine and serotonin; bidirectional blood pressure normalisation; increased bone density; reduced cartilage lesions.

The injectable's multiple-injury advantage rests on local BPC-157 concentration plus systemic TB-500 distribution. An oral presentation has no injection site, so both arms are systemic-only at unknown bioavailability. Neither arm is independently titratable in a fixed pill.

Benefits

Evidence grades: what the labels mean

Human trials Supported by randomised or placebo-controlled human trials.
Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
Animal or lab only Shown in animal or cell studies only; not yet tested in people.
Anecdotal No published studies; based on user reports or theory.

Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.

Faster tendon and ligament healing, including tendon reattaching to bone, with fewer adhesions and stiff bands afterwards — the main use for the pairing.Animal or lab only
Faster muscle recovery, with better-structured muscle fibres, plus increased muscle size and strength.Anecdotal
Support for healing after orthopaedic surgery, with surgeon approval.Anecdotal
Joint support for chronic inflammation and wear and tear, usually over a longer run.Animal or lab only
Faster wound healing with less scar tissue and more organised new tissue.Animal or lab only
Reduced inflammation in the nervous system, muscles, tendons, joints, and damaged tissue, through two different routes.Animal or lab only
New blood vessels form by two separate routes, improving blood flow and oxygen delivery.Animal or lab only
More collagen, which improves skin condition and elasticity and promotes hair growth.Anecdotal
Gut benefits from the BPC-157 half: heals ulcers, protects against damage from anti-inflammatory painkillers, and speeds healing of the colon in inflammatory bowel disease.Animal or lab only
Protects the brain from free radical damage, supports memory and mood, and relieves pain by raising dopamine and serotonin.Animal or lab only
Brings blood pressure back toward normal from either direction, increases bone density, reduces joint pain, and strengthens the immune response.Animal or lab only
Recruits stem cells and satellite cells toward damaged tissue.Animal or lab only
Convenience specific to this product: both peptides in one swallowed pill, with no mixing and no injection.Anecdotal

Tendon and ligament repair including tendon-to-bone integration, fibroblast outgrowth and migration, improved ligament biomechanics, and prevention of adhesions and fibrous bands.Animal or lab only
Muscle fibre regeneration with improved structure and biomechanics, myoblast chemoattraction, hypertrophy, and strength.Anecdotal
Post-surgical recovery support after ACL reconstruction, rotator cuff repair, meniscus surgery, and soft tissue procedures.Anecdotal
Chronic joint support via dual-pathway anti-inflammatory action and tissue remodelling.Animal or lab only
Accelerated wound healing: re-epithelialisation up 42% at day 4 and 61% at day 7 in rats, with organised mature collagen and reduced scarring.Animal or lab only
Anti-inflammatory activity across CNS, muscle, tendon, and damaged tissue via COX-2, IL-6, and TNF-alpha reduction (BPC-157) and Ac-SDKP (TB-500).Animal or lab only
Angiogenesis through two pathways — VEGFR2 upregulation and direct VEGF/endothelial stimulation — improving perfusion and oxygenation.Animal or lab only
Collagen synthesis with dermal thickening, improved elasticity, and hair growth promotion.Anecdotal
Enteric activity from the BPC-157 arm: ulcer healing, protection against NSAID-induced mucosal damage, accelerated colonic healing in inflammatory bowel disease, gut–brain axis modulation.Animal or lab only
CNS antioxidant protection, memory preservation, mood regulation, and analgesia via central dopamine and serotonin elevation.Animal or lab only
Bidirectional blood pressure normalisation, increased bone density, reduced cartilage lesions and joint pain, strengthened host-defence growth factor production.Animal or lab only
Stem cell and satellite cell mobilisation toward damaged tissue.Animal or lab only
Presentation-specific: fixed-ratio oral delivery of both arms in a single unit, no reconstitution, no injection.Anecdotal

What to expect

Everything below comes from injectable use of the pairing. No study has looked at healing timelines for the swallowed pill.

The published data is thin. In one small review of 16 knee-pain patients given a single injection into the joint of BPC-157 alone or BPC-157 plus thymosin beta-4, 14 of 16 (87.5%) reported significant pain relief lasting 6 months to a year. Of the 4 who got the combination, 3 of 4 (75%) improved. That is far too few people to say the pair beats either one alone.

What users report, which is weaker evidence:

Weeks 1 to 2. Pain and inflammation usually ease first. Some people feel tired or slightly flu-like for the first few days, more often blamed on the TB-500 half. This normally passes within 24 to 48 hours.

Weeks 3 to 4. Function improves for tendon and ligament injuries. Movements that hurt start to become possible and range of motion improves.

Weeks 6 to 8. Peak results for most injuries.

Muscle injuries tend to respond faster (2 to 4 weeks) than tendons (4 to 8 weeks). Chronic or old injuries take longer (8 to 12 weeks) and results are less predictable. Some users report no benefit at all, especially with long-standing degenerative problems.

This is not an overnight fix. The body still has to heal; the peptides support the process, they do not skip it. Take it every day for weeks and judge progress against where you started.

All timeline data derives from injectable use; no study has assessed the oral co-formulation.

Published: Lee and Padgett (2021), a retrospective, uncontrolled chart review of 17 chronic knee pain patients given intra-articular BPC-157 alone (12) or BPC-157 plus thymosin beta-4 (4). Of 16 contactable at follow-up, 14 (87.5%) reported significant pain relief lasting 6 months to 1 year after a single injection; 11 of 12 (91.6%) in the monotherapy group and 3 of 4 (75%) in the combination group. No standardised outcome measures; no inference about combination superiority is possible.

BPC-157 half-life is under 30 minutes, hepatic metabolism, renal excretion, urinary detection up to 4 days. TB-500 subcutaneous pharmacokinetics are unpublished; the frequently cited approximately 10-day half-life is not from a published study.

User-reported course, anecdotal: weeks 1–2, reduced pain and inflammation, with transient fatigue or mild flu-like symptoms in the first days attributed to the TB-500 arm, resolving within 24 to 48 hours; weeks 3–4, functional improvement and range of motion gains in tendon and ligament injuries; weeks 6–8, peak response for most injury types. Muscle injuries respond in 2 to 4 weeks, tendons in 4 to 8 weeks, chronic or older injuries in 8 to 12 weeks with less predictable outcomes.

Response is not universal. Reports include complete resolution of chronic rotator cuff pain within 3 weeks on BPC-157 at 500 mcg daily, and also MRI-confirmed shoulder degeneration with no benefit from 250 mcg twice daily for 4 weeks. Variability is greatest in chronic and degenerative presentations.

The process is biological healing, accelerated rather than bypassed; consistent daily exposure over weeks is required to judge response.

Reconstitution and dosing

There is nothing to mix. Each pill contains 500 mcg of BPC-157 plus 500 mcg of TB-500, which is 1,000 mcg of peptide in total.

There are two options. Take one pill once a day, or take one pill twice a day, morning and evening. The twice-daily option is double the total amount, not the same amount split in two. A run lasts 6 to 8 weeks, followed by 2 to 4 weeks off, dosing every day. Take it at any time of day. You do not have to be fasted, but dosing fasted may work better, so avoid taking it close to a large meal, especially a high-fat one.

For comparison, the injectable blend is dosed at 250 to 500 mcg of each peptide once a day, at any time, for 4 to 8 weeks of active healing: 4 to 6 weeks for a fresh strain, sprain, or tear; 4 to 8 weeks after surgery with surgeon approval; 6 to 8 weeks for chronic injury or joint support; 500 mcg daily for 6 to 8 weeks if several injuries are healing at once. By body weight, the injectable guide is 250 mcg daily under 150 lbs, 250 to 400 mcg at 150 to 200 lbs, and 400 to 500 mcg over 200 lbs. Chronic or deep damage may be extended to 8 to 12 weeks. Injectable guidance says these healing peptides do not need cycling off; use them while tissue is damaged and reduce or stop once healed.

How much of a swallowed pill is absorbed is not known for either peptide, and the TB-500 half is not known to survive stomach acid, so the injectable figures cannot be converted directly to the pill. For gut problems alone, plain oral BPC-157 may be the better fit. Mild nausea is more often reported with BPC-157 above 500 mcg a day. If you are using both the pill and the injection, count the total from both.

No reconstitution. Each unit delivers 500 mcg BPC-157 + 500 mcg TB-500, a 1,000 mcg total peptide load in a fixed 1:1 ratio.

Oral protocol: 1 pill once daily, or 1 pill twice daily AM/PM; the latter doubles total daily exposure rather than splitting it. Run 6–8 weeks with a 2–4 week washout, daily throughout, any time of day. Fasting is not required but may increase efficacy; avoid dosing near large meals, particularly high-fat ones. No selection criterion and no ceiling is given.

Injectable reference protocol for the same pairing: 5 mg BPC-157 + 5 mg TB-500 (10 mg vial) reconstituted with 2 mL bacteriostatic water, giving 250 mcg of each peptide per 10 units; 250 to 500 mcg of each peptide once daily (10 to 20 units) subcutaneously, no fasting requirement, for 4 to 8 weeks of active healing. By application: acute injury 250 to 500 mcg daily for 4 to 6 weeks; post-surgical 250 to 500 mcg daily for 4 to 8 weeks with surgeon approval; chronic injury or joint support 250 to 500 mcg daily for 6 to 8 weeks; multiple simultaneous injuries 500 mcg daily for 6 to 8 weeks. By body weight: under 150 lbs 250 mcg; 150 to 200 lbs 250 to 400 mcg; over 200 lbs 400 to 500 mcg of each. Chronic or deeper damage extends to 8 to 12 weeks. No cycling mechanism exists for these non-hormonal compounds; dose until healed, then reduce or stop — a position that sits against the oral entry's 2–4 week washout, and the two have not been reconciled.

No published dose-finding exists for the combination by any route; the practical protocols represent clinical practice patterns and what users report. Studied doses are individual: BPC-157 10 mcg/kg to 10 mg/kg in animals, human single doses up to 20 mg IV, 4000 mcg intra-articular, 10 mg intravesical; TB-500 Phase I IV doses 42 mg to 1260 mg.

Oral-specific gaps: no bioavailability figure for either arm, no gastric stability data for TB-500, and daily TB-500 exposure versus the separate-vial pattern of 2.5 mg twice weekly reported by users. Nausea is more associated with BPC-157 above 500 mcg per day. For gut-specific goals, oral BPC-157 alone may be preferable. NSAIDs present mixed data with BPC-157 and are a soft interaction, not a hard contraindication.

Standard

Cycle: 6–8 weeks, then a 2–4 week washout · Frequency: Daily; any time of day. Fasted dosing is not required but may increase efficacy; avoid dosing close to large meals, particularly high-fat ones

When	Dose	How often
Once daily	1 pill (500 mcg BPC-157 + 500 mcg TB-500)	1×/day
Twice daily (double the daily total, not a split of it)	1 pill (500 mcg BPC-157 + 500 mcg TB-500) AM and 1 pill PM — 1,000 mcg of each per day	2×/day

Alternative protocols

Alternative protocols reflect older community practice and are kept for reference.

Alternative, Oral pills — 500 mcg BPC-157 + 500 mcg TB-500 per pill

When	Dose	How often
Standard protocol	1 pill (500 mcg BPC-157 + 500 mcg TB-500)	1×/day
Twice-daily option (double the daily total, not a split of it)	1 pill (500 mcg BPC-157 + 500 mcg TB-500) AM and 1 pill PM — 1,000 mcg of each per day	2×/day

Who should avoid it

Both peptides are in every pill at a fixed ratio, so a warning that applies to either one rules out this product. You cannot drop or lower one half on its own.
Anyone with an active cancer or tumour. Both peptides encourage new blood vessel growth, which in theory could feed a tumour. This is a precaution based on how they work, not on reported cases. The standalone TB-500 page also excludes anyone in cancer treatment or with cancer in the family.
Anyone with a past cancer, a precancerous condition, or an unexplained lump. Talk to your oncologist first; imaging clearance before starting is essential.
Anyone known to be allergic to BPC-157, TB-500, or thymosin peptides. BPC-157 is itself a protein, so people with a protein allergy should be careful.
Anyone pregnant or breastfeeding. There is no safety data, and the standalone BPC-157 (oral) page notes BPC-157 is toxic to a developing fetus.
Anyone with a severely weakened immune system.
Anyone with an autoimmune condition. TB-500 changes how the immune system behaves, and BPC-157 stimulates it, so either could make the condition worse.
Anyone with a heart or circulation condition, or being treated for one. BPC-157 may raise blood pressure, and the standalone BPC-157 (oral) page excludes anyone with QT prolongation, a heart rhythm problem seen on an ECG (a heart-rhythm tracing).
Anyone with liver or kidney disease, including chronic kidney disease or kidney damage from a toxic substance. Both organs clear the peptides and may be strained.
From the standalone TB-500 page: anyone with a blood clotting disorder affecting the face.
Painkillers like ibuprofen (NSAIDs). The data is mixed: BPC-157 may protect the gut from NSAID damage, but NSAIDs may blunt its healing effect. Not a hard stop, but be aware.
From the standalone BPC-157 (oral) page: blood thinners such as warfarin, Eliquis, Xarelto, and high-dose aspirin, because BPC-157 may affect clotting.
From the standalone BPC-157 (oral) page: brain-acting medicines such as SSRIs and SNRIs (two families of antidepressant), benzodiazepines, and antipsychotics, because BPC-157 affects dopamine and serotonin.
From the standalone BPC-157 (oral) page: medicines that change immune function, such as biologics, steroids, and immunosuppressants.
Competitive athletes. Both peptides are banned by WADA and by the UFC, NFL, NCAA, NHL, MLB, NAIA, and PGA. Neither is FDA approved; in 2023 the FDA placed both in Category 2, barring them from compounded medicines.
There is no set blood test for this stack. If you are using it for an injury, have a doctor or physiotherapist track your progress.

Fixed 1:1 oral co-formulation: a contraindication to either arm is a contraindication to the product, since the arms cannot be dose-separated.
Active malignancy or tumour — contraindicated. Both arms are pro-angiogenic (VEGFR2 upregulation from BPC-157, VEGF signalling and endothelial effects from TB-500), and thymosin beta-4 overexpression has been associated with metastatic potential in some tumour types. A 2025 review found BPC-157 inhibits uncontrolled proliferation in tumour contexts in animal models; the exclusion is precautionary and mechanistic. The standalone TB-500 page also excludes ongoing oncological treatment and family history of cancer.
History of malignancy, precancerous conditions, or unresolved masses — oncologist consultation and imaging clearance before use.
Known hypersensitivity to BPC-157, TB-500, or thymosin peptides; peptide or protein hypersensitivity generally.
Pregnancy and lactation — no safety data; the standalone BPC-157 (oral) page describes BPC-157 as fetotoxic and treats it as an absolute contraindication.
Severe immunodeficiency — caution.
Active autoimmune disease — caution; TB-500 is immunomodulatory and BPC-157 immunostimulatory, either of which may exacerbate the underlying condition.
Cardiovascular disease or ongoing cardiovascular treatment — caution; BPC-157 may raise blood pressure, and the standalone BPC-157 (oral) page lists QT prolongation as a contraindication.
Hepatic or renal impairment, including chronic kidney disease and nephrotoxicity — BPC-157 is hepatically metabolised and renally excreted, adding clearance burden to compromised organs.
From the standalone TB-500 page: facial blood clotting disorder — contraindicated.
NSAIDs — mixed data. BPC-157 counteracts NSAID-induced gut injury in some research; other work suggests NSAIDs may interfere with its regenerative mechanisms. Not a hard contraindication.
From the standalone BPC-157 (oral) page: anticoagulants and antiplatelets — warfarin, DOACs such as apixaban and rivaroxaban, high-dose aspirin — via possible effects on clot dynamics.
From the standalone BPC-157 (oral) page: neuroactive agents — SSRIs, SNRIs, benzodiazepines, antipsychotics — via central dopamine and serotonin modulation.
From the standalone BPC-157 (oral) page: immune-modulating drugs — biologics, corticosteroids, immunosuppressants.
No known interaction between BPC-157 and TB-500 themselves; no well-established drug interactions overall, reflecting limited human research rather than demonstrated safety.
Regulatory: FDA Category 2 bulk drug substance (both, 2023); WADA S0 prohibited; banned by UFC, NFL, NCAA, NHL, MLB, NAIA, PGA; not approved for human therapeutic use and not legal for sale as a drug, food, or supplement in the US.
Monitoring: no established bloodwork panel. Periodic clinical assessment of healing progress is the practical approach.

Side effects

Most users report few or no side effects, and most of what is reported fades within the first few days.
Tiredness or a mild flu-like feeling in the first 1 to 3 days. This is the most consistently reported effect, usually blamed on the TB-500 half. It typically passes within 24 to 48 hours and fades with later doses.
Mild nausea. Uncommon, and more linked to BPC-157 above 500 mcg per day — which the twice-daily option of this pill reaches.
Headache, dizziness, or lightheadedness. Users of the injectable describe a brief head rush after injecting; whether a swallowed pill produces the same has not been established.
From the standalone BPC-157 (oral) page: diarrhoea, gas or bloating, and changes in appetite.
From the standalone TB-500 page: muscle pain, bloating if you have irritable bowel syndrome, and muscle spasms or odd muscle contractions if the dose is too high.
From the standalone TB-500 page: signs of an allergic reaction — rash, hot flushes, facial swelling, itching, trouble breathing, or heavy sweating. Stop and get medical help if these appear.
Injection site redness, swelling, or bruising is common with the injectable version but does not apply here, because nothing is injected.
A theoretical worry: both peptides grow new blood vessels, which could in principle feed an existing tumour. No study has shown either peptide causes cancer in a healthy person.
In animal studies BPC-157 showed no toxicity to liver, kidneys, or genes at doses up to 20 mg/kg, and TB-500 showed none at up to 100 mg/kg. Short-term human trials found no serious problems, but long-term safety is unknown, and the FDA has flagged BPC-157 for immune reaction risk and impurities in unregulated products.

Adverse effects are reported as minimal and transient by most users. No published study has assessed the safety of the combination at practical doses; the absence of harm in short-term trials does not establish long-term safety.
Fatigue, lethargy, or flu-like symptoms during the first 1 to 3 days — the most consistently reported effect, attributed primarily to the TB-500 arm, typically resolving within 24 to 48 hours and attenuating with subsequent doses.
Mild nausea — uncommon, more associated with BPC-157 above 500 mcg per day; the twice-daily option of this presentation delivers 1,000 mcg of BPC-157 daily.
Headache, dizziness, and lightheadedness. Post-injection head rush subsiding within minutes is reported with the parenteral blend; oral equivalence is not documented.
From the standalone BPC-157 (oral) page: diarrhoea, flatulence and bloating, appetite changes in either direction.
From the standalone TB-500 page: myalgia; bloating in irritable bowel syndrome; dose-dependent muscle spasm or altered contraction from actin and myosin overstimulation.
From the standalone TB-500 page: hypersensitivity — rash, hot flushes, facial oedema, pruritus, dyspnoea, profuse sweating. Discontinue and seek medical attention.
Injection site reactions (erythema, swelling, bruising) are common with the parenteral blend and not applicable to an oral presentation.
Gastrointestinal overlap between the arms — nausea, bloating, diarrhoea — is the plausible locus for additive tolerability problems on an oral route; no available data separates them.
Theoretical: dual pro-angiogenic activity in the presence of existing malignancy; thymosin beta-4 overexpression is associated with metastatic potential in certain tumour types, while a 2025 review found BPC-157 inhibits uncontrolled proliferation and downregulates VEGF in tumour contexts in animal models. No study shows either peptide causes cancer in a healthy organism.
Preclinical toxicology: BPC-157 showed no acute hepatic, renal, mutagenic, or teratogenic toxicity at up to 20 mg/kg; TB-500 showed no significant adverse effects at up to 100 mg/kg in rodents. Human data: 2 healthy adults received IV BPC-157 up to 20 mg with no adverse events; Ruff et al. 2010 and Wang et al. 2021 gave IV TB-500 up to 1260 mg to a combined total of over 100 volunteers with no dose-limiting toxicities. The FDA has flagged BPC-157 for immune reaction risk, peptide impurities in unregulated products, and lack of human safety data.

What the evidence shows

No controlled study has tested BPC-157 and TB-500 together against either one alone, and no study has looked at the two together in a swallowed form. The case for the pair rests on research into each peptide separately, plus one small combined study — all of it using injections.

That combined study, Lee and Padgett (2021), reviewed the records of 17 people with long-standing knee pain who had injections into the knee joint. Twelve got BPC-157 alone and 4 got BPC-157 plus thymosin beta-4. Of the 16 who could be reached afterwards, 14 (87.5%) reported significant pain relief lasting 6 months to 1 year from a single injection. In the BPC-157-only group 11 of 12 (91.6%) improved; in the combined group 3 of 4 (75%) improved. With only 4 people in the combined group, it says nothing about whether the pair beats BPC-157 alone.

For BPC-157, a 2025 systematic review in HSS Journal covered 36 studies — 35 in animals and 1 in humans. It confirmed the healing mechanisms and found no toxicity to any organ at doses up to 20 mg/kg in animals. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine found BPC-157 actually slows uncontrolled cell growth in animal tumour models. Three small human studies exist: a safety study in 2 adults given IV doses up to 20 mg with no adverse events, a bladder study in 12 women where 10 of 12 had complete symptom relief, and the knee study above.

For TB-500, Malinda et al. (1999) found it sped wound closure in rats by 42% at day 4 and 61% at day 7. Ehrlich and Hazard (2010) found treated wounds healed with minimal scarring and no loss of strength. Xu et al. (2013) found it improved the strength of healing knee ligaments in rats. Two human safety studies (Ruff et al. 2010 with IV doses up to 1260 mg, and Wang et al. 2021 with 84 volunteers) found it well tolerated.

What this means for you: the animal evidence for each peptide is strong; the human evidence is thin; the evidence for the pair is one tiny study; and the evidence for swallowing TB-500 is absent. BPC-157 is known to survive stomach acid. TB-500 is not known to, and no absorption data exists for it in a pill.

No controlled study has examined the BPC-157 + TB-500 combination head-to-head against either monotherapy, and none has examined the combination by the oral route. The evidence base is the individual compound literature plus one small retrospective combination series, all parenteral.

Lee and Padgett (2021): retrospective chart review of 17 patients with chronic knee pain receiving intraarticular injections. Twelve received BPC-157 alone, 4 received BPC-157 plus thymosin beta-4; doses in the combination arm were not specified. Of 16 reachable at follow-up, 14 (87.5%) reported significant pain relief lasting 6 months to 1 year after a single injection — 11 of 12 (91.6%) in the monotherapy arm, 3 of 4 (75%) in the combination arm. Uncontrolled, no standardised outcome measures, no functional or quality-of-life instruments. Supports safety and analgesic signal in a small sample; permits no inference on combination superiority, equivalence, or inferiority.

BPC-157: a 2025 systematic review in HSS Journal covered 36 studies (35 preclinical, 1 clinical), confirming angiogenesis, fibroblast activation, and anti-inflammatory mechanisms with no acute toxicity in any organ system at up to 20 mg/kg. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine reported BPC-157 inhibits uncontrolled proliferation and downregulates VEGF in tumour contexts in animal models. Human pilots: IV infusion up to 20 mg in 2 healthy adults without adverse events; intravesical use in 12 women with interstitial cystitis, 10 of 12 achieving complete symptom resolution; the knee series above. Mechanistic support includes VEGFR2 upregulation with Akt-eNOS signalling (Hsieh et al., 2017), FAK-paxillin activation and tendon outgrowth (Chang et al., 2011), and growth hormone receptor upregulation in tendon fibroblasts (Chang et al., 2014).

TB-500: Malinda et al. (1999) — re-epithelialisation increased 42% at day 4 and 61% at day 7 in rat wounds, with improved contraction and collagen deposition. Ehrlich and Hazard (2010) — minimal scarring, preserved breaking strength, organised mature collagen. Xu et al. (2013) — improved biomechanical properties of healing rat medial collateral ligament with uniform fibre bundles and increased fibril diameter. Phase I: Ruff et al. 2010 (IV up to 1260 mg) and Wang et al. 2021 (84 volunteers), no dose-limiting toxicities. Subcutaneous pharmacokinetics are unpublished; the widely repeated 10-day half-life has no pharmacokinetic source.

Route-specific gap: gastric stability is documented for BPC-157 only. No oral bioavailability figure exists for either arm, and none for TB-500 in any oral vehicle.

User reports

From public forums

Everything users report about this pair comes from the injected version. No user reports exist for the pill, so treat the timelines below as a rough guide only.

Weeks 1 to 2: most people first notice less pain and swelling. Some feel tired or slightly flu-ish for the first few days, usually blamed on the TB-500 half; it clears within 24 to 48 hours.

Weeks 3 to 4: movement that used to hurt starts to feel easier, and range of motion improves, especially for tendon and ligament injuries.

Weeks 6 to 8: peak results for most injuries. Muscle injuries tend to respond faster (2 to 4 weeks) than tendons (4 to 8 weeks). Old or chronic injuries take longer (8 to 12 weeks) and results are less predictable.

Individual accounts: one user with long-standing rotator cuff pain at age 46 was pain-free within 3 weeks on 500 mcg of BPC-157 daily injected near the shoulder, and repeated the result at age 50. Another had old lower back pain gone within 8 injections and shoulder popping improved within 4 days. A tennis elbow log using TB-500 at 2.5 mg twice weekly and BPC-157 at 350 mcg twice daily near the elbow reported the ache fading by week 2 and a return to the gym after about 5 weeks.

Not everyone benefits. Some with MRI-confirmed shoulder degeneration saw nothing from 250 mcg twice daily for 4 weeks. Others described it as no better than saline, or as months of wasted money. Chronic and degenerative problems are where results vary most.

On blend versus separate: users prefer a blend for simplicity, and separate products when they want to change one dose independently, run different lengths, or place BPC-157 at the injury. A pill removes the placement option entirely.

This is not an overnight fix. Healing still has to happen; consistent daily use over weeks is what users describe.

All user reporting concerns the subcutaneous blend or separately injected components. No reports exist for the oral co-formulation; the following is carried across with that caveat.

Typical timeline in practice: weeks 1 to 2, reduced pain and inflammation, with some users reporting initial fatigue or mild flu-like symptoms attributed to the TB-500 arm, resolving within 24 to 48 hours. Weeks 3 to 4, functional improvement and expanding range of motion in tendon and ligament injuries. Weeks 6 to 8, peak response for most injury types. Muscle injuries respond in roughly 2 to 4 weeks, tendon injuries 4 to 8 weeks, chronic or older injuries 8 to 12 weeks with less predictable outcomes.

Representative accounts: chronic rotator cuff tendon pain at age 46 resolving within 3 weeks on BPC-157 500 mcg daily injected peri-lesionally, reproduced on recurrence at age 50; old lower back pain resolved within 8 injections with shoulder crepitus improving within 4 days; a tennis elbow log on TB-500 2.5 mg twice weekly plus BPC-157 350 mcg twice daily near the elbow, ache subsiding by week 2 and full gym return after approximately 5 weeks.

Non-responders are well represented: MRI-confirmed shoulder degeneration unchanged after 250 mcg twice daily for 4 weeks; comparisons to saline; months of use with no perceived effect. Variability clusters in chronic, long-standing, and degenerative presentations.

Blend versus separate vials: the blend is preferred for one reconstitution and one injection; separate vials when independent titration, differing cycle lengths (BPC-157 typically 4 to 8 weeks, TB-500 sometimes longer), or peri-lesional BPC-157 with abdominal TB-500 is wanted. The oral presentation forfeits site-targeting and independent titration, and its daily TB-500 exposure differs in pattern from the twice-weekly injectable schedules users describe.

Users consistently describe the stack as accelerating rather than bypassing the biological repair process, requiring consistent daily use over weeks.

User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.

Stacking

BPC-157 + TB-500 blend (injectable)
The injected version of the same pairing, and the form all the research and user reports describe. Choose it when you want to treat one specific injury, because an injection can be placed near the damaged area — a pill cannot.
Same two arms, parenteral. The injectable retains peri-lesional placement for the BPC-157 arm and is the presentation the evidence and user reporting refer to. If both presentations are in use, count total daily exposure across them rather than treating them as separate protocols.
BPC-157 (oral)
The BPC-157 half on its own as a capsule. BPC-157 alone may be enough for mild injuries and is more suitable for gut-specific use, since only BPC-157 survives stomach acid. Its entry carries most of the same warnings listed above.
Standalone oral BPC-157 allows independent titration of that arm and carries the same contraindication and interaction set listed above. For enteric indications, BPC-157 alone is the more appropriate choice: gastric stability belongs to BPC-157, not TB-500.
TB-500
The TB-500 half on its own, injected. Its entry carries the TB-500 warnings and side effects listed above, and it is the only place a TB-500 dose is given in milligrams.
Standalone TB-500 carries that arm's adverse effect and contraindication profile, and its 1–2.5 mg twice-weekly schedule is the only stated TB-500 dosing reference — a very different exposure pattern from daily oral dosing.
GHK-Cu
Works alongside the pair: the stack handles cell movement, new blood vessels, and scar prevention, while GHK-Cu handles collagen remodelling. Keep them as separate products — the copper in GHK-Cu can degrade TB-500 if stored together in one vial.
Mechanistically complementary: cell migration, angiogenesis, and antifibrotic activity from the stack; collagen remodelling and copper-dependent repair from GHK-Cu. TB-500 contains methionine that can oxidise in the presence of copper if co-formulated in one vial; at standard use rates (a vial finished within 20 to 30 days) the loss is minimal, but separate storage preserves potency. The oral pill sidesteps the co-storage issue.
GLOW
A ready-made blend of TB-500, BPC-157, and GHK-Cu in one injectable vial, for those who want all three without managing separate products.
Pre-blended TB-500 + BPC-157 + GHK-Cu (10 mg + 10 mg + 50 mg), an injectable alternative to combining this pair with GHK-Cu separately.
KLOW
A four-part injectable blend of TB-500, BPC-157, KPV, and GHK-Cu, adding an anti-inflammatory peptide to the GLOW combination.
Pre-blended TB-500 + BPC-157 + KPV + GHK-Cu, extending the GLOW combination with KPV for additional anti-inflammatory activity.
CJC-1295 No DAC
No interaction concerns, but different timing. Growth hormone peptides need an empty stomach to work well; this pill does not. Keep the GH peptide on its own fasted schedule and take the pill whenever convenient.
No interaction. GH secretagogues require fasting for optimal GH release; the repair stack does not. Keep the GHRH analogue on its fasted schedule and dose the pill independently. Syringe co-drawing guidance for the injectable blend is irrelevant to an oral presentation.
Ipamorelin
No interaction concerns. Take ipamorelin fasted as its own protocol requires; the pill can be taken at any time.
No interaction. Ipamorelin retains its fasted timing requirement; the oral repair stack is timing-independent, so the schedules simply run in parallel.
Sermorelin
No interaction concerns. Keep sermorelin on its fasted schedule and take the pill separately whenever suits you.
No interaction. Sermorelin's fasted timing constraint is unaffected by concurrent oral BPC-157 + TB-500.
GLP-1 agonists (retatrutide, semaglutide, tirzepatide)
No interaction concerns. They work in completely different ways and can be run at the same time. The warning against drawing them into one syringe with the injectable blend does not arise with a pill.
No interaction; distinct mechanisms and pathways, no timing conflict. The prohibition on co-mixing in a syringe (different reconstitution ratios, volumes, and schedules) applies to the injectable blend only.
Testosterone replacement therapy
No interaction concerns. The pill can be taken alongside TRT without adjustment.
No interaction. Runs alongside testosterone replacement therapy without adjustment to either protocol.

Common questions

Can BPC-157 and TB-500 be started together from day one?

Yes. There is no reason to start one before the other. They work in different ways and do not interfere with each other, and the pill contains both from the first dose anyway.

Yes. The arms act through non-overlapping mechanisms — growth factor signalling, VEGFR2 and FAK-paxillin for BPC-157; actin sequestration and Ac-SDKP release for TB-500 — with no known interaction between them. Sequential introduction has no rationale, and the fixed co-formulation removes the option.

Is the blend better than taking BPC-157 or TB-500 alone?

Nobody has tested that. The only combined study, Lee and Padgett (2021), had 4 people in the combined group — too few to say. The argument for the pair is that they cover different stages of healing. For mild injuries or gut problems, BPC-157 alone may be enough.

No controlled comparison exists. Lee and Padgett (2021) had 4 patients in the combination arm (3 of 4, 75%, improved) against 11 of 12 (91.6%) on BPC-157 alone, which permits no inference. The rationale is mechanistic coverage of more of the repair cascade. For mild injuries and enteric indications, BPC-157 monotherapy may suffice.

Does the pill need to be cycled?

No: these are healing compounds, not hormones, so use them while tissue is damaged and reduce or stop once healed. Typical runs are 4 to 8 weeks, extended to 8 to 12 weeks for chronic or deep damage. The existing dosing guidance for this pill uses 6 to 8 weeks on and 2 to 4 weeks off, which sits within that range.

No biological mechanism requires cycling off; the compounds are non-hormonal. Standard runs are 4 to 8 weeks for acute injury, extendable to 8 to 12 weeks for chronic or deeper damage, with dose reduction or cessation once healing is achieved. The existing 6–8 week on, 2–4 week washout pattern for this presentation is consistent with that guidance.

Does it need to be taken fasted?

Not required. Neither peptide interacts with food the way growth hormone peptides do. The dosing guidance for this pill notes fasted dosing may work better and suggests avoiding large, fatty meals around the dose, but the main thing is to be consistent.

Not required. Neither arm interacts with nutrient absorption or insulin signalling in the way GH secretagogues do. Existing dosing notes for this presentation state fasted dosing may increase efficacy and advise avoiding proximity to large, high-fat meals; consistency matters more than timing.

Does a swallowed pill target a specific injury?

No. With injections, BPC-157 works hardest near where it is placed, because it clears from the body in under 30 minutes. A pill cannot be placed anywhere. TB-500 spreads through the whole body regardless of route, so the pill relies on body-wide action. If one specific injury is the goal, the injectable is the better fit.

No. BPC-157 has a half-life under 30 minutes and concentrates peri-lesionally after injection; oral delivery forfeits that entirely. TB-500 has low molecular weight, does not bind extracellular matrix, and distributes systemically by any route. The oral presentation therefore offers systemic coverage only. Note also that no oral absorption data exists for TB-500.

Can it be taken with other peptides?

Yes. There are no known interaction concerns with GLP-1 drugs, growth hormone peptides, TRT, or GHK-Cu. Growth hormone peptides need their own fasted timing. The only warnings about mixing in one syringe apply to the injectable version.

Yes. No interaction concerns are stated with GLP-1 agonists, GH secretagogues, TRT, or GHK-Cu. GH peptides retain their fasted schedule. Syringe co-mixing prohibitions and the copper-methionine oxidation concern with GHK-Cu relate to the injectable blend and do not arise with an oral unit.

Is it legal or allowed in sport?

Neither peptide is FDA approved. In 2023 the FDA put both in Category 2, barring them from compounded medicines, and they cannot be sold as a drug, food, or supplement in the US. Both are banned by WADA and by the UFC, NFL, NCAA, NHL, MLB, NAIA, and PGA.

Both are FDA Category 2 bulk drug substances (2023), not approved for human therapeutic use, and not legal for sale as a drug, food, or dietary supplement in the US. Both are WADA-prohibited under S0 and banned by UFC, NFL, NCAA, NHL, MLB, NAIA, and PGA.

References

This entry has been reviewed and expanded with additional reference material. Units are recomputed from the stated protocol.